Curis (CRIS) Projected to Post Quarterly Earnings on Thursday

Curis (NASDAQ:CRIS) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($2.29) per share and revenue of $1.00 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Curis (NASDAQ:CRIS) last released its earnings results on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93. On average, analysts expect Curis to post ($15.65) EPS for the current fiscal year and ($57.10) EPS for the next fiscal year.

Curis Trading Up 12.8%

NASDAQ CRIS opened at $0.45 on Thursday. The business’s 50-day moving average price is $0.96 and its 200 day moving average price is $9.27. Curis has a twelve month low of $0.33 and a twelve month high of $31.80. The company has a market capitalization of $948,860.00, a PE ratio of -0.03 and a beta of 3.11.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Curis in a research note on Monday, August 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a report on Thursday, October 15th. Wall Street Zen raised shares of Curis from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Finally, Zacks Research upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $43.00.

About Curis

Curis, Inc is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation.

Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.